Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 22INDUSTRY 6OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Conditions

Cancer Pain 2

Interventions

Cisplatin 50Capecitabine 42apatinib 34Radiotherapy 33Oxaliplatin 33Gemcitabine 33Cyclophosphamide 32Drug Therapy 31Paclitaxel 30Carboplatin 29tislelizumab 27Irinotecan 27Fluorouracil 26Docetaxel 26Bevacizumab 23Surgical Procedures, Operative 21Nivolumab 19pembrolizumab 18fludarabine 18Radiation 16Metformin 16Exercise 16camrelizumab 15S 1 (combination) 14Control Groups 14Blood Specimen Collection 14Pemetrexed 13Standard of Care 12anlotinib 11Neoadjuvant Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Hydromorphone × Clear all
NCT04785768 2025-05-22

IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration

Fujian Cancer Hospital

Phase 3 Completed
1,372 enrolled

Cancer Pain

NCT03375515 2021-03-08

PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain

Fujian Cancer Hospital

Phase 3 Completed
214 enrolled

Cancer Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡